John Throup, Ph.D.
Dr. Throup joins Jnana from Bristol Myers Squibb (BMS) where he was most recently Vice President and Development Lead responsible for leading the development of assets in the Immunology pipeline across early and late development. Most recently, Dr. Throup led the development of the TYK2 inhibitor, deucravacitinib, from preclinical to NDA and MAA submission. Before joining BMS in 2014, Dr. Throup spent 15 years at GlaxoSmithKline (GSK) in operational and strategic leadership roles across the R&D organization. Dr. Throup received his Ph.D. in molecular microbiology from the University of Nottingham, UK.